4Wright C, Mellon K, Johnston P, et al. Expresson of mutant p53, CerbB-2 and the epidemal growth factor receptor in transitional cell carcinoma of the human urinary bladder[J].Br J Cancer, 1991,63(6) :967 - 970.
5Lermoine NR, Staddon S,Dickson C,et al. Absence of activating transmembrane mutations the C-erbB-2 proto-oncogene in human breast cancer cer[J], Oncogene, 1990,5(2) :237 - 239.
6Rodenhuis S, Slebos RJ,Boot AJ,et al. Incidence and possible clinical significance of k-ras oncogene activation in adenocarcinoma of the human lung[J]. Cancer Res, 1988,48(20) :5738 - 5741.
7Hall PA,Levison DA, Woods AL, et al. Proliferating cell nuclear antigen(PCNA) immunolocalization in paraffin section: an index of cell proliferation with evidence of deregulated expression in some neoplasms [J]. J Pathol, 1990,162(4) :285 - 294.
8Poller DN, Galea M, Pearson D, et al. Nuclear and flow cytometric characteristics associated with over expression of the C-erhB-2 oncoprorein in breast carcinoma[J]. Breast Cancer Res Treat, 1991,20(1):3- 10.
9deJong .IS, vanDiest PJ, vander Valk P,et al. Expressicm of growth factors, growth-lnhihiting factors and their receptors in invasive breast cancer H: correlations with proliferation and angiogenesis[J]. J Pethol,1998,184(1):53-57.
10Loachim E, Kamina S, Athanassiadon S, et al. The prognostic significance of epidermal growth factor receptor(EGFR), C-erbB-2, ki-67 and PCNA expression in breast cancer[J]. Anticancer Res, 1996, 16(5B) :3141 - 3147.
